Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2007 May 22;96(12):1871–1878. doi: 10.1038/sj.bjc.6603812

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2007 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Synergistic antitumour effect of a combination of gene therapy with IR treatment. (A) Ad/EFp-BCD or Ad/5HREp-BCD was intratumorally injected into tumor-bearing mice on day 0 (blue arrow head), and 5-FC was administered daily from day 1 to day 5 (red arrow head). Body weight of the tumour-bearing mice was measured during and after the treatment. The results are the mean of six independent mice±s.d. ^*P<0.05. ^**P<0.01. (B and C) Tumour-bearing mice in the Ad & 5-FC group and Ad & 5-FC & IR group were administered Ad/5HREp-BCD. Those in the Ad & 5-FC group, IR & 5-FC group, and Ad & 5-FC & IR group were administered 5-FC. The tumour xenografts in the IR group, IR & 5-FC group, and Ad & 5-FC & IR group were locally exposed to irradiation with a single dose of 12.5 Gy (B) or daily dose of 3 Gy for 5 days (C). (See Materials and methods for details.) Tumour volume was measured with calipers and calculated as 0.5 L W². Relative tumour volume indicates the ratio of the tumour volume on each day to the corresponding volume on day 0. The results are the mean of six independent tumours±s.d.